

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10575745	
	Filing Date		2006-04-10	
	First Named Inventor	Yigal M. Pinto		
	Art Unit			
	Examiner Name	unknown		
Attorney Docket Number		6049-00100		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575745
Filing Date	2006-04-10
First Named Inventor	Yigal M. Pinto
Art Unit	
Examiner Name	unknown
Attorney Docket Number	6049-00100

/GC/	1	Boluyt et al. "Matrix gene expression and decompensated heart failure: The aged SHR model," Cardiovascular Research, 2000, pp. 239-249.	<input type="checkbox"/>
/GC/	2	Broers et al. "Dynamics of the nuclear lamina as monitored by GFP-tagged A-type lamins," Journal of Cell Science, 1999, pp. 3463-3475.	<input type="checkbox"/>
/GC/	3	Cherayil et al. "Molecular cloning of a human macrophage lectin specific for galactose," Proc. Natl. Acad. Sci. USA, 1990, pp. 7324-7328.	<input type="checkbox"/>
/GC/	4	Cleutjens et al. "Collagen Remodeling after Myocardial Infarction in the Rat Heart," American Journal of Pathology, 1995 pp. 325-338.	<input type="checkbox"/>
/GC/	5	Hein et al. "Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanism, Circulation, Journal of the American Heart Association, 2003, 984-991.	<input type="checkbox"/>
/GC/	6	Bolli, "Clinical strategies for controlling peaks and valleys: type 1 diabetes," JCP, 2002; 10 pages.	<input type="checkbox"/>
/GC/	7	Giordanengo et al. "Anti-galectin-1 autoantibodies in human Trypanosoma cruzi infection: differential expression of this β -galactoside-binding protein in cardiac Chagas' disease," Clin. Exp. Immunology, 2001, pages 266-273.	<input type="checkbox"/>
/GC/	8	Kostin et al. "Myocytes Die by Multiple Mechanisms in Failing Human Hearts," Circulation Research, April 18, 2003, pages 1-10.	<input type="checkbox"/>
/GC/	9	Lorell et al. "Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis," Circulation, 2000, pages 470-479.	<input type="checkbox"/>
/GC/	10	Mathews et al. "Evidence for IgG Autoantibodies to Galectin-3, a β -Galactoside-Binding Lectin (Mac-2, ϵ Binding Protein, or carbohydrate Binding Protein 35) in Human Serum," Journal of Clinical Immunology, 1995, pages 329-336.	<input type="checkbox"/>
/GC/	11	Pokharel et al. "N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts," Hypertension, August 2002, pages 155-161.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575745
Filing Date	2006-04-10
First Named Inventor	Yigal M. Pinto
Art Unit	
Examiner Name	unknown
Attorney Docket Number	6049-00100

/GC/	12	Tan et al. "The gene expression fingerprint of human heart failure," PNAS, August 20, 2002, pages 11387-11392.	<input type="checkbox"/>
/GC/	13	Topol et al. "Single Nucleotide Polymorphisms in Multiple Novel Thromboxopndin Genes May Be Associated With Familial Premature Myocardial Infarction." Circulation, November 27, 2001, pages 2641-2644.	<input type="checkbox"/>
/GC/	14	Vasan et al. "Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study." Circulation, March 24, 2003 1486-1491.	<input type="checkbox"/>
/GC/	15	Cleutjens et al. "Thrombospondin 2 Deficiency in Mice Results in Cardiac Rupture Early after Myocardial Infarction, Circulation, November 2, 1999, abstract.	<input type="checkbox"/>
/GC/	16	PCT Search Report and Written Opinion for International Application No. PCT/EP2004/10879, mailed November 25, 2004, 14 pages.	<input type="checkbox"/>
/GC/	17	International Preliminary Report, for International Application No. PCT/EP2004/10879, mailed September 20, 2005.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Gary Counts/	Date Considered	06/22/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.